Stock Market Reviews

Read and share opinions on GOVX (GeoVax Labs, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
  Nov 14, 2025
• GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
  Nov 10, 2025
• GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
  Nov 4, 2025
• GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
  Nov 3, 2025
• BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
  Oct 30, 2025
• GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
  Oct 29, 2025
• GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
  Oct 28, 2025
• GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
  Oct 16, 2025
• GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
  Oct 9, 2025
• GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
  Oct 7, 2025
• GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
  Oct 1, 2025
• GeoVax Labs Announces $2.5 Million Registered Direct Offering
  Sep 30, 2025
• GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
  Sep 29, 2025
• GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
  Sep 24, 2025
• GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
  Sep 22, 2025
• GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
  Sep 18, 2025